Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2022 - 2024)

Ginkgo Bioworks Holdings (DNA) has reported Asset Writedowns and Impairment for 3 consecutive years, with $47.9 million the latest figure, recorded in Q2 2024.

• For the quarter ending Q2 2024, Asset Writedowns and Impairment rose 431.7% year-over-year to $47.9 million; the trailing twelve-month figure through Sep 2025 stood at $47.9 million (down 70.14% YoY), and the FY2024 full-year result was $4.8 million, down 96.03% from the prior year.
• Asset Writedowns and Impairment fell to $47.9 million in Q2 2024 per DNA's latest filing, from $112.4 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $112.4 million in Q3 2023 and bottomed at -$10.1 million in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $39.8 million across 3 years, with a median of $28.4 million in 2023.
• The widest YoY moves for Asset Writedowns and Impairment: up 431.7% in 2024, down 431.7% in 2024.
• Over 3 years, Asset Writedowns and Impairment stood at -$10.1 million in 2022, then soared by 1212.9% to $112.4 million in 2023, then tumbled by 57.42% to $47.9 million in 2024.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $47.9 million, $112.4 million, and $9.0 million for Q2 2024, Q3 2023, and Q2 2023 respectively.